How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!
Knowing how to read a balance sheet is a key skill investors need to know,…
- ASX: IVX
Invion Ltd
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Copmany Overview
About Invion
Invion’s product pipeline consists of PhotoSoft, a PDT (Photodynamic Therapy platform) involving a light-sensitive drug to selectively target and kill tumour cells. Preliminary clinical data and case reports are promising, and the company is on its way to larger studies in Australia and New Zealand, with possible registration of this technology. IVX-P02 might offer a new targeted approach to the treatment of cancer via PDT.
Invion Company History
Invion is an Australian biotech company established in 2012 with the purpose of developing new approaches in oncology. First, it focused on respiratory diseases but then moved its focus to the treatment of cancer, transferring its experience to PDT product development. The lead candidate, IVX-P02, is a new approach to cancer treatment by using drugs activated with light that precisely target and kill cancer cells. The strategic deal that Invion signed with the Hudson Institute of Medical Research in 2017 significantly developed its R&D capabilities. It has been a slow and steady journey but the company has been undertaking Phase I/II studies including in non-melanoma skin cancer and anogenital cancer. Late 2025 saw FDA Orphan Drug Designation for anal cancer, which provides major development incentives if the therapy progresses.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of Invion (ASX: IVX)
The outlook for Invion is cautiously optimistic. Though the development of the PDT drug, IVX-P02, may create potential in treating a variety of cancers, this path to regulatory approval is ongoing, and clinical trials have yet to mature. On the other hand, its partnerships with institutions such as Hudson Institute of Medical Research could hasten such a process. Not to mention the additional fund-raising that will need to be done and sorting out such a complex regulatory environment. Nevertheless, this program is aimed at working toward some successful advancement of Invion’s pipeline and technologies portfolio. With successful preclinical data and early-stage trials underway in Australia and New Zealand, Invion is poised to play a key role in the future landscape of cancer treatment. The timeline for commercialisation, though, cannot be estimated with clarity until further advanced trial results come through, although this is realistically 4-5 years away.
— Our Assessment
Is Invion (ASX: IVX) a Good Stock to Buy?
Analysts generally remain cautious on Invion at such an early stage of its clinical trials and with no near-term profitability in sight. While focused on PDT, which does hold potential in the treatment of cancer, this remains a speculative stock as outcomes are dependent on clinical success and, ultimately, regulatory approval. Some would point out promising partnerships, such as that with the Hudson Institute, but in general, they emphasize the extremely high risk of investing in small biotech companies that have not yet attained any revenue or regulatory milestones.
— Our Stock Analysis
Related Articles
Adisyn (ASX:AI1) Graphene Breakthrough, What Investors Need To Know
Adisyn may have a fix for the Chip Industry's Wiring Problem
Think about the wiring…
NEXTDC (ASX:NXT) Record 667MW Contracted & A$2.2B Capital Plan
S4 hits 71% contracted as utilisation jumps 60% to 667MW
NextDC (ASX:NXT) has added 250MW…
TSMC’s (NSDQ:TSM) Money Printer, March Revenue $13.1B, Margins Hit 58%
Record Margins, AI Demand Still Accelerating
TSMC (NSDQ:TSM) continues to show real pricing power. Demand…
ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%
Net orders beat revenue 1.2x, yet investors punished machine sales
ASML (NASDAQ:ASML) sits at the…
Michael Hill (ASX:MHJ): This Under Pressure Jewellery Outlet Is Trying To Position Itself As An AI P...
In this era, every company is trying to position itself as an AI play -…
— Faq
Frequently Asked Questions
What’s Invion all about in medical research?
Invion is at the forefront with a method called PhotoDynamic Therapy (PDT) for cancer treatment. They use a special agent, IVX-PDT, drawn from their Photosoft™ Technology, aiming to treat cancer more effectively with fewer side effects.
How is Invion’s IVX-PDT different from usual cancer treatments?
IVX-PDT is Invion’s unique approach that specifically targets cancer cells, aiming to minimize the unpleasant side effects and discomfort often seen with traditional treatments. It’s a big step forward in making cancer care better for patients.
Where does Invion have the right to use its technology?
Invion has the green light to use its Photosoft™ Technology across a wide stretch of the Asia Pacific, except for a few places like China (but Hong Kong’s in), Macau, Taiwan, and Japan, covering cancer treatments, atherosclerosis, and infectious diseases.
Any big partnerships for Invion?
Absolutely! Invion has joined forces with leading research powerhouses like the Peter MacCallum Cancer Centre and also teamed up with Dr.inB to work on developing Photosoft™ for treating HPV. It shows they’re all about collaborating to push research forward.
What big achievements has Invion recently hit?
Recently, Invion made significant progress with its skin cancer trial and also managed to extend its exclusive rights into South Korea. These steps mark important milestones on Invion’s journey, highlighting their steady march towards making a significant impact in healthcare.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
